M&A NEWS

J&J agrees US$2.2bn upfront deal for Ollin Biosciences

The acquisition brings a Phase 3 bispecific that beat Roche's Vabysmo on anatomic measures in a head-to-head study, with Blackstone funding late-stage trials.

M&A News deals deskHealthcare / Biotech · United States, Americas16 Nov 2026

Johnson & Johnson said on 16 November 2026 it would acquire Ollin Biosciences for US$2.2bn upfront, with up to about US$1.125bn more in regulatory and commercial milestones.

Why Johnson & Johnson is buying Ollin Biosciences, Inc.

The deal adds OLN324, a Phase 3 bispecific antibody targeting VEGF and Ang2 for retinal vascular diseases including wet AMD and diabetic macular edema. J&J's Kip Connor said OLN324 selectively targets two important drivers of retinal disease. Ollin also has a preclinical programme, OLN102, for thyroid eye disease and Graves' disease.

Deal terms and financing

Blackstone will pay J&J US$750m over several years to fully fund OLN324's Phase 3 development, receiving regulatory and sales milestones and single-digit royalties; the arrangement depends on the acquisition closing. J&J said it would give the accounting impact on or before closing.

Regulatory approvals and timing

The transaction is subject to applicable regulatory approvals and customary closing conditions and is expected to close before the end of 2026.

Market context

Ollin, backed by investors including ARCH Venture Partners and Mubadala Capital, raised US$330m in mid-2026 to fund Phase 3 trials. The Financial Times had reported advanced talks valuing Ollin at up to US$3.4bn.

More United States M&A news

All United States deals →